The recent layoffs of hundreds of drug sales reps mean there are fewer people in the field calling on doctors to see what they are prescribing. But they don't have to--drugmakers have found new tools that actually can tell them more about doctors' prescribing patterns than the physicians even know themselves.
The drugmaker has been fined by the French Competition Authority for "disparaging" generic copies of its now-off-patent bloodthinner, Plavix.
South Africa plans to revamp its intellectual-property laws to make it more difficult for pharma companies to win protection for new versions of older drugs. The move comes soon after India's top court backed strict requirements for drug patents.
After losing patent protection last year on the blockbuster antidepressant Lexapro, Danish drugmaker Lundbeck hopes to regain a least a bit of that vaporized revenue as it launches its anti-binge drinking drug Selincro in some European countries.
Purdue's original patent on the superpotent and often abused painkiller OyxContin expires tomorrow, and drugmakers are jockeying for a piece of its $2.8 billion market share. But the FDA is under increasing pressure to require generic drugmakers to make their formulations tamper-resistant.
A union fund is suing Warner Chilcott, Watson Laboratories and Lupin, claiming that their Loestrin 24 Fe patent settlements amounted to unfair market-sharing deals that cost payers money. Warner's key patent on the formula was weak, the fund claims, and the generics makers only backed away because Warner paid them to.
Pfizer's potential liability on off-label Neurontin use just grew: A U.S. appeals court in Boston upheld a $142 million verdict in one lawsuit and reinstated two others that had been tossed out by lower courts--including a class action that could allow hundreds of health plans to pursue claims against the company
A U.S. court has ruled against AstraZeneca in a long-running patent fight over its asthma drug Pulmicort Respules. That means copycat drugmakers can launch their versions, competing with Teva Pharmaceutical's authorized generic.
Easter promises to be a nail-biting weekend for Novartis. That's because a final verdict in the big Glivec patent case is due on Monday from India's Supreme Court. So, the Swiss drugmaker will finally win its patent for the cancer treatment--or not.
It is a not-so-happy anniversary for Germany's Bayer AG. A year after the company became the first to have a drug targeted by India's compulsory licensing law, an appeals board has said there will be no going back on Nexavar.